We canโt show the full text here under this license. Use the link below to read it at the source.
Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting
Link between different forms of semaglutide and eye side effects in real-world use
AI simplified
Abstract
A total of 1733 ocular adverse event reports were identified from the FDA database, with 1541 linked to subcutaneous semaglutide and 192 to oral semaglutide.
- Most adverse events occurred within the first month of treatment, with median times to onset of 7.00 days for injectables and 3.50 days for tablets.
- 5.41% of patients using subcutaneous semaglutide and 2.17% of those on oral semaglutide reported after one year.
- Female patients showed a higher susceptibility to ocular adverse reactions than male patients.
- Blurred vision was the most common adverse event associated with oral semaglutide, accounting for 34.33% of the reports.
- Subcutaneous semaglutide was linked to a higher frequency of specific retinal complications compared to oral semaglutide.
AI simplified
Key numbers
1541 vs. 192
Ocular ADE Reports ( vs. )
Total ocular ADE reports from for each dosage form.
34.33%
Blurred Vision Incidence
Percentage of blurred vision cases among semaglutide .
62.72%
Female ADE Reporting Rate
Proportion of ocular ADE reports from female patients.